Health Care

Insider sales spiked as GSK sealed its $124‑per‑share takeover of Nuvalent, revealing a 3.5‑million‑share sell‑off and highlighting how the merger could fast‑track delivery tech into GSK’s pipeline.

Discover how Structure Therapeutics’ chief scientist’s insider trades reveal deep‑value buying, strategic liquidity, and confidence in the company’s biopharma pipeline and market‑access prospects.

Fortrea insiders buy shares amid leadership shuffle, signaling confidence in its undervalued stock and growing clinical pipeline.

Stewart Lee Hyosig’s 3,125‑share sale is a routine tax‑withholding move, not a sell‑off. Insider buying keeps confidence high as Bausch Health’s CNS and eye‑therapy pipeline shines.

United Therapeutics CEO’s 9,500‑share purchase signals executive confidence and aligns shareholder interests—an insider buy hinting at future growth.

BioCardia insider buying trend: CEO Altman Peter’s latest $0.88 purchases signal confidence amid steep valuation pressure, urging investors to watch clinical milestones.

Insider sales at BillionToOne Inc. show disciplined portfolio management—executives harvest gains while buying options, underscoring confidence in its diagnostics growth and market momentum.

Inside OMADA Health’s latest insider moves: chief accountant buys low, sells high and exercises options—what this means for investors and stock volatility.

TRAWS COO’s 93k unexercised options reveal steady confidence—not a bull rush—highlighting long‑term pipeline upside and cautious investor sentiment.

Opaleye Management’s new stake in SOL‑GEL boosts its share from 15% to 16.4%, backing the firm’s growing dermatology pipeline and value‑based reimbursement strategy.